Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Biodistribution of Radiolabeled Biologics: Combining Imaging with qPCR for Enhanced Resolution

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Biodistribution of Radiolabeled Biologics: Combining Imaging with qPCR for Enhanced Resolution

CELL & GENE | RNA | BIOLOGICS

To accurately characterize the in vivo fate of a novel biologic, a dual-modality approach combining non-invasive imaging with tissue-based qPCR offers the most comprehensive data package. This method provides both a macro-level view of whole-body distribution kinetics and a micro-level, quantitative assessment of therapeutic nucleic acid presence in specific target and non-target tissues. Integrating these datasets de-risks development by providing definitive evidence of delivery, persistence, and potential for non-target tissue biodistribution, directly supporting IND-enabling safety and efficacy evaluations.

    What is the primary advantage of combining imaging with qPCR for biodistribution?

    A: This approach provides complementary data. Non-invasive imaging (e.g., SPECT, PET) visualizes the dynamic, whole-body distribution over time, while qPCR delivers highly sensitive, absolute quantification of therapeutic nucleic acids or the therapeutic payload within harvested tissues at specific endpoints.

    How does radiolabeling affect the biologic’s function?

    A: We employ validated conjugation chemistries and select appropriate radioisotopes (e.g., Iodine-125, Zirconium-89) to ensure that the labeling process has minimal to no impact on the biologic’s structural integrity, binding affinity, or functional activity.

    What level of sensitivity can be achieved with qPCR in tissue samples?

    A: Our GxP-validated qPCR assays can detect extremely low copy numbers per microgram of genomic DNA. This high sensitivity is necessary for accurately assessing non-target tissue biodistribution and establishing a comprehensive safety profile.

    Is this dual approach compliant with regulatory expectations?

    A: Yes. A combined methodology generates a robust data package that aligns with global regulatory guidance (FDA, EMA) for characterizing the pharmacokinetic and safety profile of advanced therapies, demonstrating a thorough understanding of the investigational product’s in vivo behavior.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Quantifying Therapeutic Delivery with Multi-Modal Resolution

A central challenge in developing advanced biologics is confirming that the therapeutic reaches its intended target tissue at a sufficient concentration while avoiding significant accumulation elsewhere. Relying on a single analytical method can provide an incomplete picture. Whole-body imaging offers a powerful, longitudinal view of distribution, but may lack the resolution to quantify payload in small tissue samples or specific anatomical substructures.

Conversely, quantitative PCR (qPCR) provides exceptional sensitivity for measuring therapeutic nucleic acids in homogenized tissue, but it cannot capture the dynamic biodistribution profile over time. By integrating these two techniques, we create a complete dataset that maps the biologic’s journey through the system and quantifies its final concentration at the cellular level.

Validating Precision Delivery Systems

The industry continues to advance highly precise administration techniques. For example, research into MRI-guided frameless stereotactic systems demonstrates a clear path toward delivering viral vectors to specific, deep-tissue targets like the cerebellar dentate nuclei (PMID: 38310346). Such sophisticated delivery platforms require equally sophisticated analytical methods to verify that the intended targeting was achieved.

A comprehensive biodistribution study confirms the success of these precise delivery strategies. Imaging can verify localization to the target region, while subsequent qPCR analysis of micro-dissected tissue confirms payload presence in the target structure and, just as importantly, its absence in adjacent non-target areas. This provides the High-Fidelity Intelligence Tracking Therapeutic Delivery needed to validate novel administration techniques and build a compelling regulatory submission.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

A scientist in protective gear pipetting a sample into a vial within a sterile laboratory hood.

A Comparative Overview: Imaging vs. qPCR

Metric Non-Invasive Imaging (SPECT/PET) Quantitative PCR (qPCR)
Resolution Macro (Organ/System Level) Micro (Tissue/Cellular Level)
Quantification Relative/Semi-Quantitative Absolute (Payload Copies/Cell)
Data Type Longitudinal (Dynamic) Terminal (Endpoint)
Application Pharmacokinetics, Whole-Body Clearance Final Tissue Concentration, Non-Target Load
Sensitivity Moderate Very High

GxP-Compliant Bioanalysis in a Dedicated Framework

At Franklin Biolabs, these complex studies are executed within our >100,000 sq ft facility, which is equipped for both in vivo work and subsequent GxP bioanalysis. Our workflow ensures data generation from study design through to the final report, supporting an accelerated 18-24 month IND timeline. This operational model has contributed to a 100% IND success rate for programs conducted since 2019 (with the Franklin Biolabs brand itself launching in 2024). All in vivo studies are performed with our strategic partners, including Bioculture Group, under an Animal Welfare program that meets AAALAC and USDA accreditation standards and is built upon the core principles of the 3Rs (Replacement, Reduction, and Refinement).

Quantifying Delivery, Validating Mechanism.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities